Business Description
Edap TMS SA
NAICS : 424210
SIC : 5122
ISIN : US2683111072
Share Class Description:
FOCL: ADRTotal Employee Number:
289Compare
Compare
Traded in other countries / regions
FOCL.USAEDA.Germany IPO Date
1997-08-01Description
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 2.75 | |||||
Debt-to-EBITDA | -0.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.08 | |||||
Beneish M-Score | -4.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.1 | |||||
3-Year EBITDA Growth Rate | -303.5 | |||||
3-Year EPS without NRI Growth Rate | -69.8 | |||||
3-Year FCF Growth Rate | -52.5 | |||||
3-Year Book Growth Rate | -37.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.64 | |||||
9-Day RSI | 72.65 | |||||
14-Day RSI | 69.56 | |||||
3-1 Month Momentum % | 15.28 | |||||
6-1 Month Momentum % | 51.41 | |||||
12-1 Month Momentum % | 150 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.34 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.4 | |||||
Days Inventory | 98.24 | |||||
Days Sales Outstanding | 71.61 | |||||
Days Payable | 74.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -5.13 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43.07 | |||||
Operating Margin % | -36.25 | |||||
Net Margin % | -42.05 | |||||
EBITDA Margin % | -38.57 | |||||
FCF Margin % | -18.68 | |||||
OCF Margin % | -13.43 | |||||
ROE % | -173.28 | |||||
ROA % | -57.15 | |||||
ROIC % | -95.05 | |||||
3-Year ROIIC % | -162.49 | |||||
ROC (Joel Greenblatt) % | -208.26 | |||||
ROCE % | -104.79 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.81 | |||||
PB Ratio | 18.8 | |||||
Price-to-Tangible-Book | 33.83 | |||||
EV-to-EBIT | -4.93 | |||||
EV-to-EBITDA | -5.04 | |||||
EV-to-Revenue | 1.94 | |||||
EV-to-Forward-Revenue | 2.31 | |||||
EV-to-FCF | -10.4 | |||||
Price-to-GF-Value | 1.12 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Earnings Yield (Greenblatt) % | -20.28 | |||||
FCF Yield % | -10.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FOCL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edap TMS SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 104.513 | ||
| EPS (TTM) ($) | -0.827 | ||
| Beta | -0.2916 | ||
| 3-Year Sharpe Ratio | -0.18 | ||
| 3-Year Sortino Ratio | -0.29 | ||
| Volatility % | 84.56 | ||
| 14-Day RSI | 69.56 | ||
| 14-Day ATR ($) | 0.235499 | ||
| 20-Day SMA ($) | 4.6205 | ||
| 12-1 Month Momentum % | 150 | ||
| 52-Week Range ($) | 1.21 - 5.24 | ||
| Shares Outstanding (Mil) | 37.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edap TMS SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edap TMS SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 136 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 135 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-28 08:30 | In 66 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 65 days | ||
| General meeting for 2026 | 2026-06-26 15:00 | In 3 days | ||
| Guidance call for 2026 | 2026-06-04 14:00 | 4.58 (-3.07%) | ||
| Focal One Investor Day | 2026-06-01 08:00 | 4.32 (-3.14%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 3.60 (+3.30%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.60 (+3.30%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-25 08:30 | 3.91 (+7.27%) |
Show
Entries
Edap TMS SA Frequently Asked Questions
What is Edap TMS SA(FOCL)'s stock price today?
The current price of FOCL is $5.08. The 52 week high of FOCL is $5.24 and 52 week low is $1.21.
When is next earnings date of Edap TMS SA(FOCL)?
The next earnings date of Edap TMS SA(FOCL) is 2026-08-28 Est..
Does Edap TMS SA(FOCL) pay dividends? If so, how much?
Edap TMS SA(FOCL) does not pay dividend.
Guru Commentaries on NAS:FOCL
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation | 2025-10-17 |
Articles on Edap TMS SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers